AP Skin 01
Latest Information Update: 28 Nov 2024
Price :
$50 *
At a glance
- Originator APstem Therapeutics
- Class Antihyperglycaemics; Cell therapies; Foot disorder therapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetes mellitus; Diabetic foot ulcer
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for preclinical development in Diabetic-foot-ulcer in USA (Parenteral)
- 28 Nov 2024 No recent reports of development identified for research development in Diabetes-mellitus in USA (Parenteral)
- 29 Oct 2020 Early research in Diabetes mellitus in USA (Parenteral) (APstem Therapeutics Pipeline, October 2020)